Pill Identifier App

ACD Solution Modified

Generic Name: anhydrous citric acid solution
Dosage Form: intravenous solution

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

ACD Solution Modified

Per your order, we have compounded ACD Solution Modified as a  solution of 10 mL in a 100 mL vial.  The characteristics of this compounded preparation are as follows

ACD Solution Modified Description

Each 100 mL vial contains 80 mg citric acid, 224 mg sodium citrate anhydrous, and 120 mg dextrose anhydrous in a sterile, non-pyrogenic solution of 10 mL. The pH of the solution has been adjusted to be between 4.5 to 5.5

ACD Solution Modified - Clinical Pharmacology

In vitro, citrate ions combine with ionic calcium in the blood and the resulting

lack of ionic calcium prevents coagulation. Blood that has been treated with citrate anticoagulants is nontoxic to the body when injected in small amounts intravenously. After injection, citrate ions are rapidly removed from the blood by the liver, polymerized into glucose, and then metabolized in the usual manner

Indications and Usage for ACD Solution Modified

ACD Solution Modified is to be used in the labeling of red blood cells for intravenous administration with Cr-51 Sodium Chromate.

Contraindications

There are no known contraindications.

ACD Solution Modified Dosage and Administration

Red Blood Cell Labeling Procedure

  1. Labeling may be performed without washing or centrifugation steps directly in the reaction vial.
  2. A 30 to 50 mL sample of whole blood is withdrawn from the patient and added aseptically to a vial of ACD Solution Modified.
  3. 50 to 150 microcuries of Sodium Chromate 51 is then injected into the reaction vial using a shielded syringe. The amount of radioactivity added to the vial will

    depend on the intended use of the labeled red blood cells.

  4. The suspension is incubated for 30 to 60 minutes at room temperature with frequent, gentle agitation.
  5. After incubation, 100 mg Ascorbic Acid Injection is injected into the vial. The ascorbic acid reduces any remaining unbound dianionic chromium 51 to the anionic state which does not penetrate red blood cells; thus in vivo labeling of red blood cells is prevented.

Storage and Handling

Store the product at room temperature

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Figure 1

ACD Solution Modified 
ACD Solution Modified solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51808-201
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ANHYDROUS CITRIC ACID (ANHYDROUS CITRIC ACID) ANHYDROUS CITRIC ACID 8 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS TRISODIUM CITRATE 22.4 mg  in 1 mL
ANHYDROUS DEXTROSE 12 mg  in 1 mL
Packaging
# Item Code Package Description
1 NDC:51808-201-01 10 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 05/23/2012
Labeler - AnazaoHealth Corporation (011038762)
Establishment
Name Address ID/FEI Operations
AnazaoHealth Corporation 011038762 MANUFACTURE
Revised: 05/2012
 
AnazaoHealth Corporation



Hide
(web5)